Introduction
Meganor 160 mg (Megestrol Acetate) is a synthetic progestational and antineoplastic medication available in both tablet and oral suspension forms. Trusted by healthcare professionals worldwide, this versatile therapeutic agent offers critical benefits for patients facing serious health challenges.
Therapeutic Applications
For Cancer Patients
Meganor tablets are specifically indicated for the palliative treatment of:
- Advanced breast carcinoma (recurrent, inoperable, or metastatic)
- Advanced endometrial carcinoma (recurrent, inoperable, or metastatic)
Important Note: Meganor is designed as a complementary treatment and should not replace currently accepted primary interventions such as surgery, radiation, or chemotherapy.
For AIDS and Cancer-Related Weight Loss
Meganor oral suspension effectively addresses:
- Anorexia and loss of appetite
- Cachexia (severe weight loss and muscle wasting)
- Unexplained significant weight reduction in patients diagnosed with AIDS or cancer
How Meganor Works
Meganor’s powerful therapeutic action works through multiple mechanisms:
- Hormone Modulation: Inhibits pituitary gonadotropin production, which decreases estrogen secretion – a critical factor in hormone-dependent cancers
- Direct Cellular Impact: Exerts cytotoxic effects directly on tumor cells
- Receptor Interaction: Modifies and can neutralize the stimulatory effects of estrogen on cancer cells
- Appetite Stimulation: Increases appetite, facilitating weight gain in patients experiencing significant weight loss
Pharmacokinetics
- Peak Plasma Concentration: Reached within 2-3 hours after oral administration
- Plasma Half-Life: 33-38 hours, allowing for consistent therapeutic levels
- Elimination: Approximately 66% excreted through urine and 20% through feces
Dosage Guidelines
Tablet Form:
- Breast Cancer: 160 mg daily
- Endometrial Carcinoma: 40-320 mg daily (divided doses)
For optimal assessment of efficacy, a minimum treatment duration of 2 months is recommended.
Oral Suspension:
- Initial Adult Dosage: 800 mg daily (20 ml/day)
Safety Profile
While generally well-tolerated, healthcare providers should be aware of potential considerations:
Contraindications:
- Known hypersensitivity to Megestrol Acetate or any components
- Pregnancy or suspected pregnancy
Common Side Effects:
- Weight gain (1-2% of patients) – a beneficial effect for those with weight loss
- Increased appetite
- Mild edema
- Occasional nausea or vomiting
Less Common Effects:
- Breakthrough uterine bleeding
- Gynecomastia
- Changes in hearing
Special Precautions:
- Caution in patients with history of thrombophlebitis
- Monitoring recommended for patients with severe liver impairment
- Potential for adrenocortical effects
Patient Care Considerations
Pregnancy & Breastfeeding:
Not recommended during pregnancy due to potential risks to the fetus. Women of childbearing potential should avoid pregnancy during treatment. Breastfeeding is not advised during therapy.
Special Populations:
- Elderly Patients: May require careful monitoring, particularly for renal function
- Pediatric Patients: Safety and effectiveness not established
Quality Assurance
Meganor 160 mg is manufactured by Eskayef Pharmaceuticals Ltd., a leading pharmaceutical company with over three decades of experience in producing world-class medications. Each batch undergoes rigorous quality control to ensure the highest standards of purity, potency, and safety.
Storage Guidelines
Store in a cool (below 30°C), dry place protected from light and moisture. Keep all medications out of reach of children.
Global Availability
Orio Pharma ensures reliable worldwide delivery of Meganor within 3-7 working days, understanding the urgency of providing life-saving medications promptly to patients in need.
Conclusion
Meganor should be used under the supervision of a healthcare specialist with regular patient monitoring. For specific questions about dosing, potential interactions, or other clinical concerns, please consult with your healthcare provider.
Trust Meganor 160 mg for effective palliative cancer treatment and management of weight loss in AIDS patients – a critical component in comprehensive care plans for challenging health conditions.
